24/7 Wall St. on MSN
Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026
Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...
A report said that the family office of founders of Ajanta Pharma, which also runs other restaurant businesses, could inject ...
Zacks.com on MSN
Here's Why Biotech ETFs Are Rallying Hard
Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.
Sun Pharma has engaged a European bank as an advisor to structure a comprehensive financial proposal that may be presented to ...
Zacks Investment Research on MSN
Is Invesco Pharmaceuticals ETF (PJP) a strong ETF right now?
The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer ...
24/7 Wall St. on MSN
Biotech Could Be One of 2026’s Biggest Winners, and This ETF Is Perfectly Positioned
Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...
Upslope Capital Management, an investment management company, released its fourth-quarter 2025 investor letter. A copy of the ...
Investors are eyeing a rebound in the U.S. biotech sector in 2026, as more companies are expected to go public amid a ...
Parnassus Core Select ETF (PRCS) targets 25 high-quality large-cap stocks for long-term growth. Read the full analysis for ...
Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in ...
The green shoots suggesting a comeback was in sight for biotech stocks last year have mostly grown into proverbial flowering plants—but one company’s precipitous year-over-year decline in market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback